Abstract 1918: InnoPanelTM -a well characterized panel of 1000 cancer cell lines for anticancer drug development

Abstract

Abstract In vitro cell line assays are broadly used in drug screening to assess drug efficacy, probe drug mechanism, discover and validate predictive biomarkers. High-throughput screen can be performed on cell line collections such as the well-known NCI-60 panel that is consisted of 60 human cancer cell lines developed by the National Cancer Institute (NCI).1Cell lines in such panels are usually well annotated for basic information such as cancer type and subtype, histopathology, and marker gene expression; many experimental parameters are also measured such as doubling time and inoculation density. The utility of cell panels is greatly enhanced with more cell lines that are thoroughly characterized for their genomics by next generation sequencing2-3. To this end, we have developed InnoPanelTM—a panel of 1000 cancer cell lines, including 800 commonly used cancer cell lines, 100 primary cell lines, and 100 engineered cell lines. These cell lines cover all major cancers and majority are genomically characterized with gene expression, mutation and copy number data. Flow cytometry data were also available for engineered cell lines to validate and characterize designed modifications, for example, Siglec-15 overexpression in the CHO-K1 human Siglec-15 cell line. All data are openly available to researchers at our online database InnopediaTM.To make InnoPanelTM-based screening more valuable and accessible to biologists, we developed a bioinformatics pipeline to automate analysis that combines genomics and efficacy data. The utility of such analysis is demonstrated by case studies. InnoPanelTMcan also be customized for a subset of the 1000 cell lines. Subpanel for selected cancer types or cell lines bearing certain features can be constructed. In summary, we developed a well characterized 1000-cell line panel as a valuable resource for researchers working on anticancer drug development.